NASDAQ:LGVN Longeveron (LGVN) Stock Forecast, Price & News $2.96 -0.05 (-1.66%) (As of 05/31/2023 ET) Add Compare Share Share Today's Range$2.95▼$3.0950-Day Range$2.52▼$4.0052-Week Range$2.50▼$8.79Volume7,627 shsAverage Volume115,819 shsMarket Capitalization$62.40 millionP/E RatioN/ADividend YieldN/APrice Target$12.50 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media Longeveron MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside322.3% Upside$12.50 Price TargetShort InterestBearish8.09% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.30Based on 2 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($0.95) to ($0.75) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.92 out of 5 starsMedical Sector650th out of 1,006 stocksPharmaceutical Preparations Industry325th out of 492 stocks 3.5 Analyst's Opinion Consensus RatingLongeveron has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $12.50, Longeveron has a forecasted upside of 322.3% from its current price of $2.96.Amount of Analyst CoverageLongeveron has only been the subject of 1 research reports in the past 90 days. Previous Next 2.0 Short Interest Percentage of Shares Shorted8.09% of the float of Longeveron has been sold short.Short Interest Ratio / Days to CoverLongeveron has a short interest ratio ("days to cover") of 2.7, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Longeveron has recently increased by 159.99%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldLongeveron does not currently pay a dividend.Dividend GrowthLongeveron does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for LGVN. Previous Next 1.8 News and Social Media Coverage News SentimentLongeveron has a news sentiment score of 0.30. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.78 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Longeveron this week, compared to 3 articles on an average week.MarketBeat Follows2 people have added Longeveron to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Longeveron insiders have not sold or bought any company stock.Percentage Held by Insiders41.57% of the stock of Longeveron is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 2.12% of the stock of Longeveron is held by institutions. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Longeveron are expected to grow in the coming year, from ($0.95) to ($0.75) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Longeveron is -3.12, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Longeveron is -3.12, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioLongeveron has a P/B Ratio of 3.84. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Longeveron (NASDAQ:LGVN) StockLongeveron Inc., a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions. The company's lead investigational product is the LOMECEL-B, a cell-based therapy product that is derived from culture-expanded medicinal signaling cells that are sourced from bone marrow of young healthy adult donors. It is conducting Phase 1 and 2 clinical trials in various indications, such as aging frailty, alzheimer's disease, metabolic syndrome, acute respiratory distress syndrome, and hypoplastic left heart syndrome. The company was incorporated in 2014 and is based in Miami, Florida.Read More Receive LGVN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Longeveron and its competitors with MarketBeat's FREE daily newsletter. Email Address LGVN Stock News HeadlinesMay 31, 2023 | americanbankingnews.comLongeveron (NASDAQ:LGVN) vs. Tonix Pharmaceuticals (NASDAQ:TNXP) Head-To-Head ComparisonMay 18, 2023 | americanbankingnews.comShort Interest in Longeveron Inc. (NASDAQ:LGVN) Declines By 6.4%June 1, 2023 | Behind the Markets (Ad)"Unknown laser company making HUGE profit from Russia-Ukraine War"On February 24th, Russia invaded Ukraine. This caused major stock losses and soaring gas prices. But it also created a HUGE opportunity for savvy investors. There's an unknown laser company that's been profiting greatly from this war... ...and from another major conflict happening 3,000 miles away. Learn more here >>>May 17, 2023 | msn.comEF Hutton Reiterates Longeveron Inc - (LGVN) Buy RecommendationMay 12, 2023 | finance.yahoo.comLGVN: Announces Results and Progress on a Devastating DiseaseMay 12, 2023 | finance.yahoo.comLongeveron Inc. Provides Corporate Update and Reports First Quarter 2023 Financial ResultsMay 12, 2023 | investorplace.comLGVN Stock Earnings: Longeveron Misses EPS, Revenue EstimatesMay 12, 2023 | msn.comPreview: Longeveron's EarningsJune 1, 2023 | Behind the Markets (Ad)"Unknown laser company making HUGE profit from Russia-Ukraine War"On February 24th, Russia invaded Ukraine. This caused major stock losses and soaring gas prices. But it also created a HUGE opportunity for savvy investors. There's an unknown laser company that's been profiting greatly from this war... ...and from another major conflict happening 3,000 miles away. Learn more here >>>May 11, 2023 | americanbankingnews.comLongeveron (LGVN) Set to Announce Earnings on FridayMay 10, 2023 | markets.businessinsider.comLongeveron Rallies 20% In Morning TradeMay 10, 2023 | finance.yahoo.comLongeveron Announces New Long-Term Survival Data from ELPIS I Trial of Lomecel-B™ for Hypoplastic Left Heart SyndromeMay 10, 2023 | msn.comLongeveron stock up 15.5% premarket after positive results in trial of treatment for rare congenital heart defect in infantsMay 10, 2023 | msn.comLongeveron spikes on long-term survival data for heart disease candidateMay 10, 2023 | markets.businessinsider.comLongeveron (LGVN) Gets a Buy from EF HuttonMay 9, 2023 | finance.yahoo.comLongeveron's Lomecel-BTM Shows Encouraging Survival Data, Keeps Hypoplastic Left Heart Syndrome Pediatric Patients Heart Transplant-FreeMay 9, 2023 | investorplace.comWhy Is Longeveron (LGVN) Stock Up 30% Today?May 8, 2023 | finance.yahoo.comLongeveron to Announce First Quarter 2023 Financial Results on May 12, 2023April 19, 2023 | finance.yahoo.comLongeveron Announces First Patient Dosed in Phase 2 Clinical Trial of Lomecel-B™ for Aging-Related Frailty in JapanMarch 29, 2023 | americanbankingnews.comEF Hutton Acquisition Co. I Reiterates "Buy" Rating for Longeveron (NASDAQ:LGVN)March 14, 2023 | finance.yahoo.comLongeveron (NASDAQ:LGVN shareholders incur further losses as stock declines 18% this week, taking one-year losses to 51%March 13, 2023 | finance.yahoo.comLGVN: Longeveron Continues Progress Toward Important TreatmentsMarch 12, 2023 | insidermonkey.comLongeveron Inc. (NASDAQ:LGVN) Q4 2022 Earnings Call TranscriptMarch 10, 2023 | finance.yahoo.comLongeveron Inc. Provides Corporate Update and Reports Fourth Quarter and Full Year 2022 Financial ResultsMarch 6, 2023 | finance.yahoo.comLongeveron to Announce Fourth Quarter and Full Year Financial Results on March 10, 2023February 28, 2023 | finance.yahoo.comLongeveron Appoints Wa’el Hashad as Chief Executive OfficerJanuary 27, 2023 | finance.yahoo.comWill Longeveron (NASDAQ:LGVN) Spend Its Cash Wisely?See More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive LGVN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Longeveron and its competitors with MarketBeat's FREE daily newsletter. Email Address LGVN Company Calendar Last Earnings3/10/2023Today5/31/2023Next Earnings (Estimated)8/11/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:LGVN CUSIPN/A CIK1721484 Webwww.longeveron.com Phone305-302-7158FaxN/AEmployees18Year FoundedN/APrice Target and Rating Average Stock Price Forecast$12.50 High Stock Price Forecast$12.50 Low Stock Price Forecast$12.50 Forecasted Upside/Downside+322.3%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($0.95) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-18,830,000.00 Net Margins-1,765.78% Pretax Margin-1,765.87% Return on Equity-87.96% Return on Assets-69.43% Debt Debt-to-Equity RatioN/A Current Ratio4.14 Quick Ratio4.14 Sales & Book Value Annual Sales$1.13 million Price / Sales55.17 Cash FlowN/A Price / Cash FlowN/A Book Value$0.77 per share Price / Book3.84Miscellaneous Outstanding Shares21,082,000Free Float12,318,000Market Cap$62.40 million OptionableNot Optionable Beta0.55 Key ExecutivesDr. Joshua Michael Hare FACC (Age 59)M.D., Co-Founder, Chief Science Officer & Chairman Comp: $449.81kMr. James Clavijo CPA (Age 56)CFO & Treasurer Comp: $481.07kMr. Paul T. Lehr J.D. (Age 54)International Exec. Director, Gen. Counsel & Sec. Comp: $465.25kDr. Kwan-Hong Min M.D. (Age 55)Ph.D., Chief Medical Officer & Interim CEO Dr. Dan Gincel Ph.D. (Age 51)Sr. VP of Strategic Collaborations & Scientific Affairs Key CompetitorsImmunomeNASDAQ:IMNMSocietal CDMONASDAQ:SCTLMainz BiomedNASDAQ:MYNZBolt BiotherapeuticsNASDAQ:BOLTAlzamend NeuroNASDAQ:ALZNView All CompetitorsInsidersJoshua HareSold 20,000 sharesTotal: $85,600.00 ($4.28/share)Joshua HareSold 20,000 sharesTotal: $74,800.00 ($3.74/share)Joshua HareSold 100,000 sharesTotal: $361,000.00 ($3.61/share)James ClavijoSold 36,955 sharesTotal: $305,248.30 ($8.26/share)View All Insider Transactions LGVN Stock - Frequently Asked Questions Should I buy or sell Longeveron stock right now? 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Longeveron in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" LGVN shares. View LGVN analyst ratings or view top-rated stocks. What is Longeveron's stock price forecast for 2023? 1 brokers have issued twelve-month price objectives for Longeveron's shares. Their LGVN share price forecasts range from $12.50 to $12.50. On average, they anticipate the company's share price to reach $12.50 in the next year. This suggests a possible upside of 322.3% from the stock's current price. View analysts price targets for LGVN or view top-rated stocks among Wall Street analysts. How have LGVN shares performed in 2023? Longeveron's stock was trading at $3.22 at the start of the year. Since then, LGVN shares have decreased by 8.1% and is now trading at $2.96. View the best growth stocks for 2023 here. Are investors shorting Longeveron? Longeveron saw a increase in short interest in May. As of May 15th, there was short interest totaling 403,500 shares, an increase of 160.0% from the April 30th total of 155,200 shares. Based on an average daily trading volume, of 152,100 shares, the days-to-cover ratio is presently 2.7 days. Approximately 8.1% of the shares of the stock are sold short. View Longeveron's Short Interest. When is Longeveron's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Friday, August 11th 2023. View our LGVN earnings forecast. How were Longeveron's earnings last quarter? Longeveron Inc. (NASDAQ:LGVN) issued its earnings results on Friday, March, 10th. The company reported ($0.21) earnings per share for the quarter, missing the consensus estimate of ($0.10) by $0.11. The firm had revenue of $0.12 million for the quarter, compared to the consensus estimate of $0.40 million. Longeveron had a negative net margin of 1,765.78% and a negative trailing twelve-month return on equity of 87.96%. When did Longeveron IPO? (LGVN) raised $30 million in an IPO on Friday, February 12th 2021. The company issued 2,700,000 shares at a price of $10.00-$12.00 per share. Kingswood Capital Markets and Alexander Capital L.P. acted as the underwriters for the IPO. What is Longeveron's stock symbol? Longeveron trades on the NASDAQ under the ticker symbol "LGVN." How do I buy shares of Longeveron? Shares of LGVN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Longeveron's stock price today? One share of LGVN stock can currently be purchased for approximately $2.96. How much money does Longeveron make? Longeveron (NASDAQ:LGVN) has a market capitalization of $62.40 million and generates $1.13 million in revenue each year. The company earns $-18,830,000.00 in net income (profit) each year or ($0.95) on an earnings per share basis. How can I contact Longeveron? Longeveron's mailing address is 1951 NW 7TH AVENUE SUITE 520, MIAMI FL, 33136. The official website for the company is www.longeveron.com. The company can be reached via phone at 305-302-7158 or via email at brendan.payne@sternir.com. This page (NASDAQ:LGVN) was last updated on 6/1/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Longeveron Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.